Posted On: 10/11/2015 7:04:51 AM
Post# of 273257
Galapagos Genomics N (GLPGF) 46.7500 $GLPGF
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 6.32 (+0.18), BIIB: 269.16 (-10.72), ZIOP: 10.92 (+0.32), BMRN: 102.69 (+1.97), PCYC: 261.25 (+1.70), CLDN: 1.12 (+0.03), HSP: 89.95 (-0.01), HRTX: 25.72 (-0.93), ANTH: 6.12 (+0.12), SHPG: 200.90 (-1.85), CLLS: 26.61 (-0.16), RTRX: 20.22 (+1.07), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), AAVL: 8.48 (+0.01), SNY: 48.75 (+0.03), PFE: 33.24 (+0.15), SLXP: 172.96 (+0.15), GSK: 40.22 (+0.06), CELG: 117.38 (-0.59), ISIS: 43.24 (+0.86), TARO: 148.37 (-0.08), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)
Galapagos on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri May 08, 12:15PM CDT
JNJ: 95.37 (+0.29), ABBV: 55.64 (-0.40)
Galapagos Moves Towards RA Deal But A Dark Horse Remains On The Horizon
EP Vantage - Seeking Alpha - Thu Apr 16, 3:57PM CDT
Galapagos ’ ( OTC:GLPGF , OTCPK:GLPYY ) oral rheumatoid arthritis drug GLPG0634 has cleared the first obstacle in the path to a full-blown licensing deal with AbbVie (NYSE: ABBV ) , hitting the primary endpoint of a crucial phase IIb trial....
Galapagos to list ADSs on Nasdaq
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:35AM CDT
Galapagos JAK-1 inhibitor successful in Phase 2 rheumatoid arthritis study
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 4:17PM CDT
Galapagos and Janssen part ways in inflammation alliance
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 6:58AM CDT
JNJ: 95.37 (+0.29)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 175.94 (+4.77), ACT: 298.98 (-2.94), MDT: 72.60 (+0.55), XON: 36.01 (+1.24), CTIC: 1.63 (-0.01), PFNX: 16.24 (+0.10), JNJ: 95.37 (+0.29), ANTM: 140.49 (+3.16), NVAX: 8.04 (+0.43), SHPG: 200.90 (-1.85), ABBV: 55.64 (-0.40), TBPH: 13.86 (+0.96), SNY: 48.75 (+0.03), ALQA: 3.56 (+0.03), REGN: 503.92 (+12.71), ONCY: 0.45 (unch), PFE: 33.24 (+0.15), SLXP: 172.96 (+0.15), EPRS: 4.89 (+0.20), AMGN: 149.59 (-0.31), NKTR: 11.34 (+0.56), ZTS: 42.80 (-0.42), GILD: 100.65 (-0.16), ACHN: 7.57 (-0.10), GERN: 3.07 (+0.10)
Galapagos awarded €1.6M grant to develop Hep B therapies
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:44AM CST
Galapagos earns milestone from AbbVie
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:09AM CST
ABBV: 55.64 (-0.40)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.61 (+0.02), AGEN: 4.81 (+0.03), NVAX: 8.04 (+0.43), ALXN: 161.08 (-3.23), PPHM: 1.07 (unch), THLD: 4.06 (+0.05), GSK: 40.22 (+0.06), OMER: 12.66 (+0.58)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 55.64 (-0.40)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 6.32 (+0.18), BIIB: 269.16 (-10.72), ZIOP: 10.92 (+0.32), BMRN: 102.69 (+1.97), PCYC: 261.25 (+1.70), CLDN: 1.12 (+0.03), HSP: 89.95 (-0.01), HRTX: 25.72 (-0.93), ANTH: 6.12 (+0.12), SHPG: 200.90 (-1.85), CLLS: 26.61 (-0.16), RTRX: 20.22 (+1.07), JUNO: 48.64 (+0.84), ABBV: 55.64 (-0.40), AAVL: 8.48 (+0.01), SNY: 48.75 (+0.03), PFE: 33.24 (+0.15), SLXP: 172.96 (+0.15), GSK: 40.22 (+0.06), CELG: 117.38 (-0.59), ISIS: 43.24 (+0.86), TARO: 148.37 (-0.08), PBYI: 79.41 (+3.89), NVS: 91.90 (-0.71)
Galapagos on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri May 08, 12:15PM CDT
JNJ: 95.37 (+0.29), ABBV: 55.64 (-0.40)
Galapagos Moves Towards RA Deal But A Dark Horse Remains On The Horizon
EP Vantage - Seeking Alpha - Thu Apr 16, 3:57PM CDT
Galapagos ’ ( OTC:GLPGF , OTCPK:GLPYY ) oral rheumatoid arthritis drug GLPG0634 has cleared the first obstacle in the path to a full-blown licensing deal with AbbVie (NYSE: ABBV ) , hitting the primary endpoint of a crucial phase IIb trial....
Galapagos to list ADSs on Nasdaq
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 8:35AM CDT
Galapagos JAK-1 inhibitor successful in Phase 2 rheumatoid arthritis study
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 4:17PM CDT
Galapagos and Janssen part ways in inflammation alliance
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 6:58AM CDT
JNJ: 95.37 (+0.29)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 175.94 (+4.77), ACT: 298.98 (-2.94), MDT: 72.60 (+0.55), XON: 36.01 (+1.24), CTIC: 1.63 (-0.01), PFNX: 16.24 (+0.10), JNJ: 95.37 (+0.29), ANTM: 140.49 (+3.16), NVAX: 8.04 (+0.43), SHPG: 200.90 (-1.85), ABBV: 55.64 (-0.40), TBPH: 13.86 (+0.96), SNY: 48.75 (+0.03), ALQA: 3.56 (+0.03), REGN: 503.92 (+12.71), ONCY: 0.45 (unch), PFE: 33.24 (+0.15), SLXP: 172.96 (+0.15), EPRS: 4.89 (+0.20), AMGN: 149.59 (-0.31), NKTR: 11.34 (+0.56), ZTS: 42.80 (-0.42), GILD: 100.65 (-0.16), ACHN: 7.57 (-0.10), GERN: 3.07 (+0.10)
Galapagos awarded €1.6M grant to develop Hep B therapies
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 6:44AM CST
Galapagos earns milestone from AbbVie
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:09AM CST
ABBV: 55.64 (-0.40)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.61 (+0.02), AGEN: 4.81 (+0.03), NVAX: 8.04 (+0.43), ALXN: 161.08 (-3.23), PPHM: 1.07 (unch), THLD: 4.06 (+0.05), GSK: 40.22 (+0.06), OMER: 12.66 (+0.58)
Galapagos - AbbVie's Best Bet For Staying Market Leader In Rheumatoid Arthritis Post Humira?
SNJBiostoxx - at Seeking Alpha - Tue Nov 11, 2:45PM CST
ABBV: 55.64 (-0.40)
(0)
(0)Scroll down for more posts ▼
